Genetic testing in women diagnosed with breast cancer decreases cost of care nationwide

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the first year). The study by Georgetown Lombardi Comprehensive Cancer Center and National Cancer Institute researchers was published April 24, in the Journal of the National Cancer Institute.
Read More

>>Hollywood's Exotic Secret For Healthy Weight Loss